TOP TIERMARKET NEWSWIRE
News & sentiment

AMYLYX PHARMACEUTICA (AMLX) — News & AI sentiment

AMYLYX PHARMACEUTICA (AMLX) news roundup. 3 stories aggregated over the last 30 days. Average 30-day sentiment is 54/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 1 sales totalling $539K — net selling of $539K. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
3
avg sentiment 54/100
Insider net (90d)
$539K
0 buys · 1 sells
Congress (90d)
0
0 buys · 0 sells

Latest stories on AMLX

Mizuho raises Amylyx stock price target to $24 ahead of trial data
Investing.com Analyst Ratings61 · neutralanalyst
Jul 20
Jul 3
Jun 30
Jun 23
Jun 10
Jun 8
Amylyx Stock: Why the Full Pipeline Story Matters
MarketBeat63 · neutralproduct/pr
May 24
May 20
May 16
May 7
Open AMLX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →